GLP 1 misinformation from TikTok keeps three in four prescribers correcting patients every week

Nearly three in four clinicians who prescribe GLP 1 drugs say they correct GLP 1 misinformation at least once a week, and one in five does it every day. The figures come from a survey of 374 providers by Tebra, a health care technology company, fielded in July 2026 and discussed by Medscape on October 26. TikTok was the most cited source of wrong ideas, followed by friends and family. The same survey found clinics spending close to nine hours a week on GLP 1 paperwork, a load that shapes how quickly patients can get an appointment.

What the provider survey found

Tebra asked 374 people who prescribe GLP 1 drugs or manage patients taking them, including physicians, nurse practitioners, physician assistants, nurses and pharmacists, according to the Tebra provider survey published on its site. The survey ran in July 2026. Some 73% of respondents said they correct patient misinformation about these drugs at least weekly, and 20% said they do so daily. Asked where the wrong ideas come from, 59% named TikTok, 54% named friends, family or word of mouth, 21% named the news and 19% named AI chatbots such as ChatGPT. More than half, 55%, said patients expect weight loss to happen faster than is realistic, at least to some degree.

The report does not say how respondents were recruited, and The survey was run by a private company rather than a public agency, so the results are best read as a snapshot rather than a national estimate. Medscape also noted that one physician it quoted, John Scala, is a medical consultant to Tebra. Even with those limits, the survey offers a rare view from the prescriber side of the counter. Most coverage of GLP 1 access looks at prices and insurance. This survey looks at the time and attention that clinicians spend before a prescription is written, which is a less visible part of access but one that every patient depends on when they book a visit to ask about treatment.

TikTok and online prescribing feed GLP 1 misinformation

Social media is the main channel, by the providers' own account. TikTok led the list at 59%, ahead of word of mouth, and the share naming AI chatbots, almost one in five, shows a newer source entering the exam room. These findings sit next to a wider problem on the same platforms. Peptide Town reported in October that TikTok peptide searches for several drug names now return a blank page, while many videos remain online. Medscape described clinicians spending appointment time undoing claims about easy weight loss and unproven dosing that patients had seen online, and some doctors said they use that interest to start broader talks about metabolic health.

TikTok led the list at 59%, ahead of word of mouth, and the share naming AI chatbots, almost one in five, shows a newer source entering the exam room.

Online prescribing adds a second layer. A research letter in JAMA by Yale researchers, published in July, reports that nearly 20% of adults taking a GLP 1 drug get the prescription online. It links much of that online supply to compounded versions sold through telehealth platforms that partner with compounding pharmacies, products that are not FDA approved. Alexa Mieses Malchuk, a family physician with Geisinger in Pennsylvania, told Medscape: "I am most alarmed by people who get their GLP-1 medication online without a lot of oversight or follow-up from a physician." Medscape reported that patients who run into side effects, rapid regain or dose confusion after buying online often turn up at their primary care clinic for help.

The time cost for clinics

GLP 1 misinformation is only part of the burden the survey describes. Providers reported spending an average of 8.7 hours a week on GLP 1 administration, which covers tasks such as prior authorizations and coverage paperwork. Some 73% said they had delayed, shortened or rescheduled some care because of GLP 1 demand. Among them, 33% had rescheduled routine wellness visits, 29% had shortened appointments, 26% had delayed appointments and 25% had moved visits for chronic disease management. Almost a third, 31%, said GLP 1 requests are harder to handle than any other high demand class of medicine, and 31% of practices had added staff, changed workflows or both to keep up with demand.

The strain shows up in the workforce too. In the survey, 35% of providers said GLP 1 demand had contributed to their own burnout, 22% said it had made them less satisfied with their job, and 20% said they were considering cutting hours, switching specialties or leaving clinical practice because of it. The table below gathers the main figures. They are self reported by respondents to one company survey, and they do not measure how many patients were turned away or waited longer. Still, for a patient trying to start or continue treatment through a regular doctor, fewer and shorter appointments can mean a slower route to a prescription, and that can push some people toward faster online options.

What patients and payers should watch

Pills may add work rather than remove it. In the survey, 76% of providers said patient interest has moved toward oral GLP 1 options in recent months, and 33% expect pills to increase their administrative load. Medscape linked that to dosing rules, variable absorption and insurance hurdles, though the survey itself does not break down the reasons. For payers, the figures point to a cost that sits outside the drug price: the clinician time spent on prior authorizations and coverage rules. Plans that change criteria often add to that time. For regulators, the link between online advice, online prescribing and patients returning to primary care with problems is a reason to keep watching the telehealth market closely.

For patients, the practical advice from the doctors quoted is simple. Bring what you have seen online to a clinician rather than acting on it alone, expect gradual results, and plan regular check ins while the dose is adjusted. Malchuk told Medscape she wants to see patients at least once a month while the dose is being raised. Compounded and online products may cost less, but they are not FDA approved, and the FDA has already sent warning letters over ads from online clinics. This survey adds a measure of how much time correcting those messages now takes from the clinicians who prescribe approved drugs.

Conclusion

GLP 1 misinformation is now a weekly task for 73% of the 374 clinicians in Tebra's survey, with TikTok the leading source and paperwork taking close to nine hours a week. The survey is a company snapshot, not a national study, but it shows how online claims and online prescribing reach primary care. Patients should check what they read with a clinician before acting on it.